I Ray-Coquard
Overview
Explore the profile of I Ray-Coquard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
136
Citations
4155
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blay J, Brahmi M, Dufresne A, Swalduz A, Avrillon V, Assaad S, et al.
ESMO Open
. 2025 Jan;
10(1):104088.
PMID: 39754984
Background: Paraneoplastic inflammatory syndrome (PIS) with fever and biological inflammation is a rare but severe condition often caused by the systemic production of interleukin 6 (IL-6) by cancer cells. We...
2.
Izarn F, Henry J, Besle S, Ray-Coquard I, Blay J, Allignet B
ESMO Open
. 2024 Dec;
10(1):104086.
PMID: 39700605
Background: Over the past two decades, the globalization of oncology clinical trials has expanded, yet significant disparities persist across countries. This study aimed to evaluate these geographical inequalities, the evolution...
3.
Alvarez Secord A, Lewin S, Murphy C, Cecere S, Barquin A, Galvez-Montosa F, et al.
Ann Oncol
. 2024 Dec;
36(3):321-330.
PMID: 39617145
Background: Mirvetuximab soravtansine-gynx (MIRV) is a first-in-class, folate receptor alpha (FRα)-targeting antibody-drug conjugate with United States Food and Drug Administration approval for FRα-positive platinum-resistant ovarian cancer. PICCOLO is a phase...
4.
Harter P, Marth C, Mouret-Reynier M, Cropet C, Lorusso D, Guerra-Alia E, et al.
Ann Oncol
. 2024 Nov;
36(2):185-196.
PMID: 39528049
Background: The use of first-line poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is increasing in advanced ovarian cancer. Understanding the efficacy of first subsequent therapy (FST) in patients experiencing disease progression...
5.
Blay J, Schiffler C, Bouche O, Brahmi M, Duffaud F, Toulmonde M, et al.
Ann Oncol
. 2024 Sep;
35(12):1157-1168.
PMID: 39241959
Background: The administration of adjuvant imatinib during 3 years is indicated after resection of primary localized GIST at high risk of recurrence, but many patients relapse afterwards. Methods: IMADGIST (NCT02260505)...
6.
Xu-Vuillard A, Guerin-Charbonnel C, Bocquet F, Cheeseman S, Kubelac P, Zenatri M, et al.
ESMO Open
. 2024 Sep;
9(9):103694.
PMID: 39232440
Background: Poly(ADP-ribose) polymerase inhibitors (PARPis) improved advanced ovarian cancer treatment. Most patients progress during or following PARPi exposure, however, with concerns about sensitivity of subsequent chemotherapy. Patients And Methods: In...
7.
Turinetto M, Ray-Coquard I, Gourley C
ESMO Open
. 2024 Apr;
9(5):102983.
PMID: 38663167
No abstract available.
8.
Ledermann J, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, et al.
Ann Oncol
. 2024 Feb;
35(3):248-266.
PMID: 38307807
The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June...
9.
Blay J, Penel N, Valentin T, Anract P, Duffaud F, Dufresne A, et al.
Ann Oncol
. 2024 Jan;
35(4):351-363.
PMID: 38246351
Background: We investigated the impact of the implementation of a network of reference centers for sarcomas (NETSARC) on the care and survival of sarcoma patients in France since 2010. Patients...
10.
Blay J, Cropet C, Mansard S, Loriot Y, de la Fouchardiere C, Haroche J, et al.
ESMO Open
. 2023 Nov;
8(6):102038.
PMID: 37922690
Background: BRAF inhibitors are approved in BRAF-mutated metastatic melanoma, non-small-cell lung cancer (NSCLC), Erdheim-Chester disease (ECD), and thyroid cancer. We report here the efficacy, safety, and long-term results of single-agent...